Progress toward in vivo use of siRNAs-II
- PMID: 22186795
- PMCID: PMC3293614
- DOI: 10.1038/mt.2011.263
Progress toward in vivo use of siRNAs-II
Abstract
RNA interference (RNAi) has been extensively employed for in vivo research since its use was first demonstrated in mammalian cells 10 years ago. Design rules have improved, and it is now routinely possible to obtain reagents that suppress expression of any gene desired. At the same time, increased understanding of the molecular basis of unwanted side effects has led to the development of chemical modification strategies that mitigate these concerns. Delivery remains the single greatest hurdle to widespread adoption of in vivo RNAi methods. However, exciting advances have been made and new delivery systems under development may help to overcome these barriers. This review discusses advances in RNAi biochemistry and biology that impact in vivo use and provides an overview of select publications that demonstrate interesting applications of these principles. Emphasis is placed on work with synthetic, small interfering RNAs (siRNAs) published since the first installment of this review which appeared in 2006.
Similar articles
-
Progress towards in vivo use of siRNAs.Mol Ther. 2006 Apr;13(4):644-70. doi: 10.1016/j.ymthe.2006.01.001. Epub 2006 Feb 14. Mol Ther. 2006. PMID: 16481219 Free PMC article. Review.
-
Amide-Modified RNA: Using Protein Backbone to Modulate Function of Short Interfering RNAs.Acc Chem Res. 2020 Sep 15;53(9):1782-1790. doi: 10.1021/acs.accounts.0c00249. Epub 2020 Jul 13. Acc Chem Res. 2020. PMID: 32658452 Free PMC article.
-
RNA interference as a gene-specific approach for molecular medicine.Curr Med Chem. 2005;12(26):3143-61. doi: 10.2174/092986705774933489. Curr Med Chem. 2005. PMID: 16375707 Review.
-
Nonviral delivery of synthetic siRNAs in vivo.J Clin Invest. 2007 Dec;117(12):3623-32. doi: 10.1172/JCI33494. J Clin Invest. 2007. PMID: 18060020 Free PMC article. Review.
-
Therapeutic face of RNAi: in vivo challenges.Expert Opin Biol Ther. 2015 Feb;15(2):269-85. doi: 10.1517/14712598.2015.983070. Epub 2014 Nov 15. Expert Opin Biol Ther. 2015. PMID: 25399911 Review.
Cited by
-
RNA interference approaches for treatment of HIV-1 infection.Genome Med. 2015 May 28;7(1):50. doi: 10.1186/s13073-015-0174-y. eCollection 2015. Genome Med. 2015. PMID: 26019725 Free PMC article.
-
Recent advances in RNA interference therapeutics for CNS diseases.Neurotherapeutics. 2013 Jul;10(3):473-85. doi: 10.1007/s13311-013-0183-8. Neurotherapeutics. 2013. PMID: 23589092 Free PMC article. Review.
-
Optimization of Ultrasound-mediated Anti-angiogenic Cancer Gene Therapy.Mol Ther Nucleic Acids. 2013 May 21;2(5):e94. doi: 10.1038/mtna.2013.20. Mol Ther Nucleic Acids. 2013. PMID: 23695537 Free PMC article.
-
Tuning response curves for synthetic biology.ACS Synth Biol. 2013 Oct 18;2(10):547-67. doi: 10.1021/sb4000564. Epub 2013 Sep 3. ACS Synth Biol. 2013. PMID: 23905721 Free PMC article.
-
Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development.Mol Pain. 2016 Jun 15;12:1744806916653969. doi: 10.1177/1744806916653969. Print 2016. Mol Pain. 2016. PMID: 27306408 Free PMC article.
References
-
- Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE., and, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–811. - PubMed
-
- Meister G., and, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431:343–349. - PubMed
-
- Pham JW., and, Sontheimer EJ. The Making of an siRNA. Mol Cell. 2004;15:163–164. - PubMed
-
- Zamore PD, Tuschl T, Sharp PA., and, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 2000;101:25–33. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources